The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a ...

No serious adverse events were reported in clinical studies with EURneffy. The extensive clinical pharmacological data of EURneffy 2 mg was comparable to AAIs, with the pharmacodynamics and ...